Introduction: Adenocarcinoma is the most common histologic type of lung cancer. To
address advances in oncology, molecular biology, pathology, radiology, and surgery of lung …

Emerging evidence indicates that cancer is primarily a metabolic disease involving
disturbances in energy production through respiration and fermentation. The genomic …

Management of patients with lung cancer continues to pose a considerable challenge to
today's oncologist. While treatment may be curative in the early stages of the disease, the …

Purpose: Advanced non–small-cell lung cancer (NSCLC) patients harboring epidermal
growth factor receptor (EGFR) mutations (deletion in exon 19 or L858R) show an impressive …

Objectives Three epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)–
afatinib, erlotinib, and gefitinib–are available for the treatment of patients with EGFR …

Platinum chemotherapeutic agents such as cisplatin are currently used in the treatment of
various malignancies such as lung cancer. However, their efficacy is significantly hindered …

Introduction• Literature review‐Molecular biology of EGFR mutations‐Clinical characteristics
of NSCLC patients with EGFR mutations‐Genetic characteristics of EGFR‐mutated tumours …

Abstract The 1st ESMO Consensus Conference on lung cancer was held in Lugano,
Switzerland on 21 and 22 May 2010 with the participation of a multidisciplinary panel of …

The tumor genome is commonly aberrant as a consequence of mutagenic insult and
incomplete DNA repair. DNA repair as a therapeutic target has recently received …

The presence of somatic mutations of the tyrosine kinase domain of the epidermal growth
factor receptor (EGFR) gene in patients with advanced nonsmall cell lung cancer (NSCLC) …